Palvella Therapeutics, Inc. is a clinical-stage biopharmaceutical company dedicated to addressing serious, rare genetic skin diseases and vascular malformations. The company's pipeline is built on its patented QTORIN platform, an anhydrous gel technology designed to deliver high concentrations of therapeutic cargo deep into the epidermis and dermis. Palvella's lead product candidate, QTORIN 3.9% rapamycin, is advancing through Phase 3 clinical trials for microcystic lymphatic malformations and Phase 2 trials for cutaneous venous malformations. The company is also developing QTORIN pitavastatin for other dermatological indications. Operating primarily in the United States, Palvella aims to provide the first FDA-approved standard of care for its targeted lifelong genetic conditions. The company became publicly traded on the Nasdaq in December 2024 following a reverse merger with Pieris Pharmaceuticals.
